FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019499376> ?p ?o ?g. }

• W2019499376 endingPage "668" @default.
• W2019499376 startingPage "661" @default.
• W2019499376 abstract "Background and Purpose Optimal treatment duration of altered fractionation schedules in head and neck cancer is still undefined. A retrospective study on local tumor control, survival, and complications of accelerated hyperfractionated irradiation in head and neck cancer was undertaken to investigate whether there was an advantage in further shortening overall time from 6.5 weeks. Methods Four hundred nineteen consecutive male patients treated with radiation alone for cure 1987–1998 were analyzed. Patients with stage I, or treated also with brachytherapy implants or chemotherapy, were excluded. Treatment with accelerated hyperfractionation was performed twice daily, at a median of 1.6 Gy/fraction, to a total median dose of 68 Gy in 39 days. The patient population was divided into two groups: those with ≤39 days overall treatment time (group A, n = 227; median, 33 days) and those with >39 days (group B, n = 192; median, 46 days). Group A received a significant median tumor dose reduction of 7% compared with group B. Results The 7-year actuarial local control (LC) rates were 59% and 48% for groups A and B, respectively (p = .02). The actuarial LC rates for T1–2 patients were 79% and 74% at 7 years for groups A and B, respectively (p = NS). Similarly, for T3–4 patients, they were 47% and 35% (p = .02), respectively. The 7-year actuarial disease-free survival (DFS) rates for groups A and B were 39% and 26% (p = .01), respectively. For stage II patients, DFS was 62% and 60% at 7 years (p = NS) for groups A and B, respectively. And similarly, for stage III–IV patients, DFS was 33% and 20% (p = .04), respectively, at 7 years. LC and DFS rates at 7 years for T4 and stage IV patients, respectively, were significantly improved in group A. Cox regression analyses for LC showed that both T stage and overall time were significant prognostic factors. Similarly, UICC clinical stage and overall time were significant prognostic factors for DFS. There was no difference in acute morbidity between the two groups: 3% of patients in both groups required tube or parenteral feeding. The 7-year actuarial probability of RTOG/EORTC grades 3–5 late effects was 15% and 13%, respectively, for each group (p = NS). Conclusions This study, with the limitations of a retrospective study, has shown a significant improvement in local tumor control and disease-free survival, in patients treated with shorter overall treatment times (median, 33 days) with an accelerated hyperfractionated irradiation schedule compared with those treated with a median duration of 46 days. No significant enhancement of acute reactions and late morbidity were observed with the shorter schedule. © 2001 John Wiley & Sons, Inc. Head Neck 23: 661–668, 2001." @default.
• W2019499376 created "2016-06-24" @default.
• W2019499376 creator A5010937182 @default.
• W2019499376 creator A5013778855 @default.
• W2019499376 creator A5044621588 @default.
• W2019499376 creator A5059960694 @default.
• W2019499376 creator A5074921739 @default.
• W2019499376 date "2001-01-01" @default.
• W2019499376 modified "2023-09-25" @default.
• W2019499376 title "Accelerated hyperfractionated irradiation for advanced head and neck cancer: Effect of shortening the median treatment duration by 13 days" @default.
• W2019499376 cites W1968634065 @default.
• W2019499376 cites W1971747664 @default.
• W2019499376 cites W1974114705 @default.
• W2019499376 cites W2006723414 @default.
• W2019499376 cites W2007022307 @default.
• W2019499376 cites W2012624981 @default.
• W2019499376 cites W2016681837 @default.
• W2019499376 cites W2020378886 @default.
• W2019499376 cites W2026132872 @default.
• W2019499376 cites W2033642006 @default.
• W2019499376 cites W2056608268 @default.
• W2019499376 cites W2058069994 @default.
• W2019499376 cites W2072840628 @default.
• W2019499376 cites W2093813257 @default.
• W2019499376 cites W2103094946 @default.
• W2019499376 cites W2105150213 @default.
• W2019499376 cites W2139473442 @default.
• W2019499376 cites W4293241248 @default.
• W2019499376 doi "https://doi.org/10.1002/hed.1093" @default.
• W2019499376 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11443749" @default.
• W2019499376 hasPublicationYear "2001" @default.
• W2019499376 type Work @default.
• W2019499376 sameAs 2019499376 @default.
• W2019499376 citedByCount "15" @default.
• W2019499376 countsByYear W20194993762012 @default.
• W2019499376 countsByYear W20194993762013 @default.
• W2019499376 countsByYear W20194993762015 @default.
• W2019499376 countsByYear W20194993762016 @default.
• W2019499376 countsByYear W20194993762017 @default.
• W2019499376 countsByYear W20194993762018 @default.
• W2019499376 crossrefType "journal-article" @default.
• W2019499376 hasAuthorship W2019499376A5010937182 @default.
• W2019499376 hasAuthorship W2019499376A5013778855 @default.
• W2019499376 hasAuthorship W2019499376A5044621588 @default.
• W2019499376 hasAuthorship W2019499376A5059960694 @default.
• W2019499376 hasAuthorship W2019499376A5074921739 @default.
• W2019499376 hasConcept C121608353 @default.
• W2019499376 hasConcept C126322002 @default.
• W2019499376 hasConcept C141071460 @default.
• W2019499376 hasConcept C146357865 @default.
• W2019499376 hasConcept C151730666 @default.
• W2019499376 hasConcept C155806632 @default.
• W2019499376 hasConcept C167135981 @default.
• W2019499376 hasConcept C2776530083 @default.
• W2019499376 hasConcept C2777416452 @default.
• W2019499376 hasConcept C2908647359 @default.
• W2019499376 hasConcept C2908786992 @default.
• W2019499376 hasConcept C2989005 @default.
• W2019499376 hasConcept C3018411727 @default.
• W2019499376 hasConcept C509974204 @default.
• W2019499376 hasConcept C71924100 @default.
• W2019499376 hasConcept C86803240 @default.
• W2019499376 hasConcept C99454951 @default.
• W2019499376 hasConceptScore W2019499376C121608353 @default.
• W2019499376 hasConceptScore W2019499376C126322002 @default.
• W2019499376 hasConceptScore W2019499376C141071460 @default.
• W2019499376 hasConceptScore W2019499376C146357865 @default.
• W2019499376 hasConceptScore W2019499376C151730666 @default.
• W2019499376 hasConceptScore W2019499376C155806632 @default.
• W2019499376 hasConceptScore W2019499376C167135981 @default.
• W2019499376 hasConceptScore W2019499376C2776530083 @default.
• W2019499376 hasConceptScore W2019499376C2777416452 @default.
• W2019499376 hasConceptScore W2019499376C2908647359 @default.
• W2019499376 hasConceptScore W2019499376C2908786992 @default.
• W2019499376 hasConceptScore W2019499376C2989005 @default.
• W2019499376 hasConceptScore W2019499376C3018411727 @default.
• W2019499376 hasConceptScore W2019499376C509974204 @default.
• W2019499376 hasConceptScore W2019499376C71924100 @default.
• W2019499376 hasConceptScore W2019499376C86803240 @default.
• W2019499376 hasConceptScore W2019499376C99454951 @default.
• W2019499376 hasIssue "8" @default.
• W2019499376 hasLocation W20194993761 @default.
• W2019499376 hasLocation W20194993762 @default.
• W2019499376 hasOpenAccess W2019499376 @default.
• W2019499376 hasPrimaryLocation W20194993761 @default.
• W2019499376 hasRelatedWork W1017215580 @default.
• W2019499376 hasRelatedWork W1977093393 @default.
• W2019499376 hasRelatedWork W2007342246 @default.
• W2019499376 hasRelatedWork W2015000215 @default.
• W2019499376 hasRelatedWork W2051706898 @default.
• W2019499376 hasRelatedWork W2078920097 @default.
• W2019499376 hasRelatedWork W2128133864 @default.
• W2019499376 hasRelatedWork W2152477107 @default.
• W2019499376 hasRelatedWork W2529376761 @default.
• W2019499376 hasRelatedWork W2809798549 @default.
• W2019499376 hasVolume "23" @default.
• W2019499376 isParatext "false" @default.
• W2019499376 isRetracted "false" @default.

• next